Abstract:Objective To detect the CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation which accepted anticoagulant therapy with Warfarin,analyze the correlations of the CYP2C9 and VKO-RC1 genetic polymorphism with the effective dose and onset time of Warfarin.Methods 222 patients with permanert non-valvular atrial fibrillation were recruited randomly and divided into different groups according to the results of anticoagulant therapy.About the Warfarin drug sensitivity of patient,we defined the low effective dose when accumulated dose of Warfarin less than 12.5 milligrams if international normalized ratio (INR) reached the target value 1.8-3.0,the high effective dose was accumulated dose of Warfarin more than or equal to 12.5 milligrams.According to this,the patients were divided into low effective dose group and high effective dose group.The shot onset time was the onset time of Warfarin less than 10 days if INR reached the target value 1.8-3.0,the long onset time was the onset time more than or equal to 10 days.According to this,the patients were divided into shot onset time group and long onset time group.The correlations of the CYP2C9 and VKORC1 genetic polymorphism with the effective dose and onset time of Warfarin were analyzed.Results (1)The age,serum creatinine(SCr) and the proportion of patients taking beta blockers in low effective dose group were significantly higher than those in high effective dose group (P＜0.05 or 0.01);the body mass index (BMI),white blood cell (WBC) count significandy lower than high effective dose group(P＜0.05);the genetic makeup of CYP2C9 rs1057910 in the two groups was significantly different(P＜0.05).(2)The age,SCr and brain natriuretic peptide (BNP) of patients in shot onset time group were significantly higher than those in long onset time group(P＜0.05 or 0.01);the BMI,WBC and left ventricular ejection fraction (LVEF) significantly lower than long onset time group (P＜0.05 or 0.01);the genetic makeup of VKORC1 rs9923231 and rs10871454 in the two groups were significantly different(P＜0.05 or 0.01).(3) The effective dose of Warfarin in patients with CYP2C9 rs1057910 CA genotype was significantly lower than that with CYP2C9 rs1057910 AA genotype (P＜0.01),the onset time of Warfarin in patients with VKORC1 rs9923231 and rs10871454 CT genotype were significantly lower than those with VKORC1 rs9923231 and rs10871454 TT genotype (P＜0.05 or 0.01).(4)Based on the influence of CYP2C9 and VKORC1 different genotype on Warfarin effective dose and onset time,we defined Warfarin drug sensitivity as highly sensitivity,low sensitivity and routine sensitivity prediction model.Conclusion Combination CYP2C9 and VKORC1 genetic polymorphism with the clinical setting of patients provided a new method for guiding Warfarin anticoagulant therapy rationally in clinic and provided guidance evidence for using genotype to adjust Warfarin dose.

Genetic Polymorphism of CYP2C9 in Patients Receiving Warfarin Anticoagulant Therapy

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Cyp4f2 Polymorphism As A Genetic Risk Factor for Major Hemorrhagic Complications in Chinese Patients on Warfarin Therapy

Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.

System Renew and Meta-Analysis of Effect in Relationship of CYP 2 C9 Genetic Polymorphisms with Warfarin in Chinese Patients

Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients

To Establish a Method for Detecting Genetic Polymorphism of CYP2C9 1075A>C and VKORC1-1639 G>A and Evaluate the Correlation of SNP with Warfarin Dose

Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients

Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

Effects of CYP2C9 and VKORC1 Genetic Polymorphisms in Chinese Han Population on Maintenance Dosage of Warfarin

Study on the Genetic Polymorphism of VKORC1 in Chinese Han Treated by Warfarin Anticoagulant Therapy

Identification and Enzymatic Activity Evaluation of a Novel CYP2C9 Allelic Variant Discovered in a Patient

Influence of CYP4F2 Genotype on Warfarin Dose Requirement–a Systematic Review and Meta-Analysis

Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients

Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin

The correlation of the Warfarin drug sensitivity with CYP2C9 and VKORC1 genetic polymorphism in patients with atrial fibrillation

The Effects of Cyp2c19 Genotype on the Susceptibility for Nephrosis in Cardio-Cerebral Vascular Disease Treated by Anticoagulation

Importance in the genetic mutation of cytochrome P4502C9 Leu359 in anticoagulation therapy with warfarin.